Newsweek op-ed cites 990 FDA adverse-event reports on compounded semaglutide
The author, hospitalized after using what he believes was a contaminated peptide batch, argues the peptide market has outpaced systems for assessing risk.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 16 10:57 ETSource: Newsweek
The wire
- 01The opinion piece reports the FDA had received 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide as of 31 May 2026.
- 02It argues patients cannot judge purity or quality from a label or supplier claims, a live issue for telehealth operators and pharmacies selling unapproved peptides.
- 03The author notes the reports do not prove causation and that his own hospitalization is anecdote, not clinical research.
From the source
Read at newsweek.comThe Peptide Boom Needs Proof, Not Promises | Opinion
As of May 31, 2026, the U.S. Food and Drug Administration had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.
